Skip to main content
SpringerLink
Log in

Cancer Pain Treatment Strategies in Patients with Cancer

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Management of cancer pain is challenging. Despite the poor evidence, opioid therapy still remains the cornerstone for the management of cancer-related pain. Opioids should be given according to the clinical presentation in the different stages of disease. There is no drug of choice, as most opioids are effective. Thus, the choice should be based on the individual characteristics of patients. Optimization of opioid therapy may allow individual treatment according to the patient’s characteristics and pain syndromes, providing timely alternatives in the different stages of disease. While most patients respond to an appropriate treatment associated with a comprehensive assessment and symptom control, a high level of experience and knowledge is necessary in determining conditions to maximize the analgesic response, eventually adding adjuvants in some specific circumstances. Alternative opioids may improve the balance between analgesia and adverse effects in the presence of a poor response to the first opioid in a large number of patients. Finally, a selected population can benefit from some interventional procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51:1070–90.

    Article  Google Scholar 

  2. Kwon JH. Overcoming barriers in cancer pain management. J Clin Oncol. 2014;32:1727–33.

    Article  PubMed  Google Scholar 

  3. Te Boveldt ND, Vernooij-Dassen MJ, Jansen A, Vissers KC, Engels Y. Pain is not systematically registered in Dutch medical oncology outpatients. Pain Pract. 2015;15:364–70.

    Article  Google Scholar 

  4. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists’ attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29:4769–75.

    Article  PubMed  Google Scholar 

  5. Oosterling A, te Boveldt N, Verhagen C, van der Graaf WT, Van Ham M, Van der Drift M, Vissers K, Engels Y. Neuropathic pain components in patients with cancer: prevalence, treatment, and interference with daily activities. Pain Pract. 2016;16:413–21.

    Article  PubMed  Google Scholar 

  6. Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, Heitzer E, Fainsinger R, Bennett MI. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med. 2013;27:714–21.

    Article  PubMed  Google Scholar 

  7. Bouhassira D, Luporsi E, Krakowski I. Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer. Pain. 2017;158:1118–25.

    Article  PubMed  Google Scholar 

  8. WHO. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2018.

    Google Scholar 

  9. Mercadante S. The use of opioids for treatment of cancer pain. Expert Opin Pharmacother. 2015;16:389–94.

    Article  CAS  PubMed  Google Scholar 

  10. Mercadante S. Cancer pain. Curr Opin Support Palliat Care. 2013;7:139–43.

    Article  PubMed  Google Scholar 

  11. Huang R, Jiang L, Liu H, et al. Comparative efficacy of therapeutics for chronic cancer pain: a Bayesian network analysis. J Clin Oncol. 2019;37:1742–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mercadante S. Reviewing without clinical background is detrimental for cancer pain management. Cancers (Basel). 2019;11:1005.

    Article  Google Scholar 

  13. Lemaire A, George B, Maindet C, Burnod A, Allano G, Minello C. Opening up disruptive ways of management in cancer pain: the concept of multimorphic pain. Support Care Cancer. 2019;27:3159–70.

    Article  PubMed  Google Scholar 

  14. Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain. 2007;11:823–30.

    Article  CAS  PubMed  Google Scholar 

  15. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. 480 Part 1: clinical considerations. J Pain Symptom Manag. 2001;21:144–50.

    Article  CAS  Google Scholar 

  16. Cherny N, Ripamonti C, Pereira J, et al. Expert working group of the European association of palliative care network strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542–54.

    Article  CAS  PubMed  Google Scholar 

  17. Mystakidou K. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II and III transfers. J Pain. 2004;5:119–32.

    Article  CAS  PubMed  Google Scholar 

  18. Mystakidou K, Befon S, Kouskouni E, et al. From codeine to transdermal for cancer pain control: a safety and efficacy clinical trial. Anticancer Res. 2001;21:2225–30.

    CAS  PubMed  Google Scholar 

  19. Mystakidou K, Befon S, Tsilika E, et al. Use of fentanyl TTS as a single opioid for cancer pain relief: a safety and efficacy trial in patients naive to mild of strong opioids. Oncology. 2002;62:9.

    Article  CAS  PubMed  Google Scholar 

  20. Mystakidou K, Tsilika E, Kouloulias V. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer. 2003;107:486–92.

    Article  CAS  PubMed  Google Scholar 

  21. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WWA. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin. 2003;19:457–69.

    Article  PubMed  Google Scholar 

  22. Vielvoye-Kerkmeer A, Mattern C, Uitendaal M. Transdermal fentanyl in opioid-naive cancer patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manag. 2000;19:185–92.

    Article  CAS  Google Scholar 

  23. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, et al. A validation study of the WHO analgesic ladder: a twostep vs three-step strategy. Support Care Cancer. 2005;13:888–94.

    Article  PubMed  Google Scholar 

  24. Klepstad P, Kaasa S, Skauge M, Borchgrevink PC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anesthesiol Scand. 2000;44:656–64.

    Article  CAS  Google Scholar 

  25. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manag. 2006;31:242–7.

    Article  CAS  Google Scholar 

  26. Zheng RJ, Fu Y, Zhu J, et al. Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction. Support Care Cancer. 2018;26:4115–20.

    Article  PubMed  Google Scholar 

  27. Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34:436–44.

    Article  CAS  PubMed  Google Scholar 

  28. Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin. 2010;26:2765–8.

    Article  CAS  PubMed  Google Scholar 

  29. Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther. 2009;31:2134–8.

    Article  CAS  PubMed  Google Scholar 

  30. Mercadante S, Adile C, Ferrera P, Pallotti MC, Ricci M, Bonanno G, Casuccio A. Methadone as first-line opioid for the management of cancer pain. Oncologist. 2022;27:323–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer. 2002;95:203–8.

    Article  CAS  PubMed  Google Scholar 

  32. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11:484–9.

    Article  CAS  PubMed  Google Scholar 

  33. Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, Bruel BM, Manchikanti L. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician. 2012;15(3 Suppl):ES39–58.

    Article  PubMed  Google Scholar 

  34. Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7): CD012592.

    PubMed  Google Scholar 

  35. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68.

    Article  CAS  PubMed  Google Scholar 

  36. Portenoy RK, Foley KM. Inturrisi CE The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990;43:273–86.

    Article  PubMed  Google Scholar 

  37. Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33:943–95.

    Article  CAS  PubMed  Google Scholar 

  38. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213–7.

    Article  CAS  PubMed  Google Scholar 

  39. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manag. 2001;2001(21):338–54.

    Article  Google Scholar 

  40. Knudsen AK, Brunelli C, Kaasa S, Apolone G, Corli O, Montanari M, Fainsinger R, Aass N, Fayers P, Caraceni A, Klepstad P, European Palliative Care Research Collaborative; European Pharmacogenetic Study. Which variables are associated with pain intensity and treatment response in advanced cancer patients? Implications for a future classification system for cancer pain. Eur J Pain. 2011;15:320–7.

    Article  PubMed  Google Scholar 

  41. Mercadante S. Opioid metabolism and clinical aspects. Eur J Pharmacol. 2015;769:71–8.

    Article  CAS  PubMed  Google Scholar 

  42. Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241–8.

    Article  PubMed  Google Scholar 

  43. Mercadante S. Opioid rotation for cancer pain: rationale and clinicalaspects. Cancer. 1999;86:1856–66.

    Article  CAS  PubMed  Google Scholar 

  44. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphineand methadone in patients with cancer pain. A retrospective study. Cancer. 1998;82:1167–73.

    Article  CAS  PubMed  Google Scholar 

  45. Moknes K, Kaasa S, Paulsen O, Rosland JH, Spigset O, Dale O. Serum concentration of opioids when comparing two switching strategies tomethadone for cancer pain. Eur J Clin Pharmacol. 2012;47:2463–70.

    Google Scholar 

  46. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine tomethadone in cancer patients with poor response to morphine. J Clin Oncol. 1999;17:3307–12.

    Article  CAS  PubMed  Google Scholar 

  47. Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S. How to switch from morphine or oxycodone to methadone in cancer patients? A randomized clinical phase II trial. Eur J Cancer. 2011;47:2463–70.

    Article  CAS  PubMed  Google Scholar 

  48. Mercadante S. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med. 2012;13:399–404.

    Article  PubMed  Google Scholar 

  49. Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157:2657–63.

    Article  CAS  PubMed  Google Scholar 

  50. Mercadante S, Marchetti P, Cuomo A, et al. Factors influencing the clinical presentation of breakthrough pain in cancer patients. Cancers (Basel). 2018;10:175.

    Article  Google Scholar 

  51. Currow DC, Clark K, Louw S, Fazekas B, Greene A, Sanderson CR. A randomized, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids. Eur J Pain. 2020;24:983–91.

    Article  CAS  PubMed  Google Scholar 

  52. Mercadante S, Portenoy RK. Understanding the chameleonic breakthrough cancer pain. Drugs. 2021;81:411–8.

    Article  PubMed  Google Scholar 

  53. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181–90.

    Article  CAS  PubMed  Google Scholar 

  54. Jandhyala R, Fullarton J. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. BMJ Support Palliat Care. 2012;2:156–62.

    Article  PubMed  Google Scholar 

  55. Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manag. 2014;47:772–85.

    Article  Google Scholar 

  56. Mercadante S, Adile C, Cuomo A, Aielli F, Cortegiani A, Casuccio A, Porzio G. Fentanyl buccal tablet vs. oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manag. 2015;50:579–86.

    Article  Google Scholar 

  57. Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Opin Res Opin. 2012;28:963–8.

    Article  CAS  Google Scholar 

  58. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.

    Article  PubMed  Google Scholar 

  59. Mercadante S. Breakthrough pain: on the road again. Eur J Pain. 2009;13:329–30.

    Article  PubMed  Google Scholar 

  60. Liu MZ, Li JD, Sun J, Zhou H, Guan S, Han Y, Zhang X, Bian JL. A comparison of the clinical effectiveness between low-dose strong opioids and non-steroidal anti-inflammatory drugs in the treatment of mild cancer pain: a randomized trial. J Pain Res. 2021;14:3411–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. McNicol E, Strassels S, Goudas L, Lau J, Carr D. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;1: CD005180.

    Google Scholar 

  62. Mercadante S, Fulfaro F, Casaccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer on morphine therapy: effect on dose-escalation and pharmacoeconomic analysis. Eur J Cancer. 2002;38:1358–63.

    Article  CAS  PubMed  Google Scholar 

  63. Magee DJ, Jhanji S, Poulogiannis G, Farquhar-Smith P, Brown MRD. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. Br J Anaesth. 2019;123:e412–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Butcher B, Hutchings E, Fazekas B, Clark K, Rowett D, Currow D. Opioid-sparing effects of ketorolac in palliative care patients receiving opioids for chronic cancer-related pain: a systematic literature review. Palliat Med. 2022;36:71–80.

    Article  PubMed  Google Scholar 

  65. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9:571–91.

    Article  CAS  PubMed  Google Scholar 

  66. Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manag. 2013;46:581–90.

    Article  Google Scholar 

  67. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25:553–9.

    Article  PubMed  Google Scholar 

  68. Matsuoka H, Iwase S, Miyaji T, et al. Additive duloxetine for cancer-related neuropathic pain nonresponsive or intolerant to opioid-pregabalin therapy: a randomized controlled trial (JORTC-PAL08). J Pain Symptom Manag. 2019;58:645–53.

    Article  Google Scholar 

  69. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manag. 2003;25:302–5.

    Article  Google Scholar 

  70. Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, Spruyt O, Rowett D, Currow DC. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30:3611–7.

    Article  CAS  PubMed  Google Scholar 

  71. Mercadante S. Ketamine: to be or not to be. Ann Palliat Med. 2013;2:37–9.

    PubMed  Google Scholar 

  72. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13:438–49.

    Article  CAS  PubMed  Google Scholar 

  73. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag. 2013;46:207–18.

    Article  Google Scholar 

  74. Lichtman AH, Lux EA, McQuade R, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55:179–88.

    Article  Google Scholar 

  75. Häuser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management: an overview of systematic reviews. Eur J Pain. 2018;22:455–70.

    Article  PubMed  Google Scholar 

  76. van den Beuken-van Everdingen MH, de Graeff A, Jongen JL, Dijkstra D, Mostovaya I, Vissers KC. Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review. Pain Pract. 2017;17:409–19.

    Article  PubMed  Google Scholar 

  77. Candido KD, Kusper TM, Knezevic NN. New cancer pain treatment options. Curr Pain Head Rep. 2017;21:12.

    Article  Google Scholar 

  78. Mercadante S, Candido KD. The use of alternative therapies in conjunction with opioids for cancer pain. Expert Rev Anticancer Ther. 2019;19:697–703.

    Article  CAS  PubMed  Google Scholar 

  79. Mercadante S, Porzio G, Gebbia V. Spinal analgesia for advanced cancer patients: an update. Crit Rev Oncol Hematol. 2012;82:227–32.

    Article  PubMed  Google Scholar 

  80. Kurita GP, Benthien KS, Nordly M, European Palliative Care Research Collaborative (EPCRC), et al. The evidence of neuraxial administration of analgesics for cancer-related pain: a systematic review. Acta Anaesthesiol Scand. 2015;59:1103–15.

    Article  CAS  PubMed  Google Scholar 

  81. Mercadante S, Klepstad P, Kurita GP, et al. Minimally invasive procedures for the management of vertebral bone pain due to cancer: the EAPC recommendations. Acta Oncol. 2016;55:129–33.

    Article  PubMed  Google Scholar 

  82. Papanastassiou ID, Philips FM, van Meirhaeghe J, et al. Comparing effects of kiphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies. Eur J Spine. 2012;21:1826–43.

    Article  Google Scholar 

  83. Health Quality Ontario. Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: a systematic review. Ont Health Technol Assess Ser. 2016;16:1–202. eCollection 2016.

  84. Katonis P, Pasku D, Alpantaki K, et al. Treatment of pathologic spinal fractures with combined radiofrequency ablation and balloon kyphoplasty. World J Surg Oncol. 2009;7:90.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Calmes V, Vallée JN, Rose M, et al. Osteoblastic and mixed spinal metastases: evaluation of the analgesic efficacy of percutaneous vertebroplasty. Am J Neuroradiol. 2007;28:570–4.

    Google Scholar 

  86. Anselmetti GC, Manca A, Montemurro F, et al. Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients. Cardiovasc Interv Radiol. 2012;35:139–45.

    Article  Google Scholar 

  87. Chew C, Ritchie M, O’Dwyer PJ, et al. A prospective study of percutaneous vertebroplasty in patients with myeloma and spinal metastases. Clin Radiol. 2001;66:1193–6.

    Article  Google Scholar 

  88. Eck JC, Nachtigall D, Humphreys SC, et al. Comparison of vertebroplasty and ballon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature. Spine J. 2008;8:488–97.

    Article  PubMed  Google Scholar 

  89. Buchbinder R, Osborne RH, Kallmes D. Vertebroplasty appears no better than placebo for painful osteoporotic spinal fractures, and has potential to cause harm. Med J Aust. 2009;191:476–7.

    Article  PubMed  Google Scholar 

  90. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361:557–68.

    Article  CAS  PubMed  Google Scholar 

  91. Papanastrassiou ID, Filis AK, Gerochristou MA, et al. Controversial issues in kyphoplasty and vertebroplasty in malignant vertebral fractures. Cancer Control. 2014;21:151–7.

    Article  Google Scholar 

  92. Mercadante S, Klepstad P, Kurita GP, Sjøgren P, Giarratano A, European Palliative Care Research Collaborative (EPCRC). Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015;96:577–83.

    Article  PubMed  Google Scholar 

  93. Koyyalagunta D, Engle MP, Yu J, Feng L, Novy DM. The effectiveness of alcohol versus phenol based splanchnic nerve neurolysis for the treatment of intra-abdominal cancer pain. Pain Physician. 2016;19:281–92.

    Article  PubMed  Google Scholar 

  94. Zomers PJW, Groenewg G, Baart S, Huygen FJP. Percutaneous Cervical Cordotomy for the Treatment of Cancer Pain: A Prospective Case Series of 52 Patients with a Long-Term Follow-Up. Pain Pract 2021;21:557–67.

  95. Doyle A, Sharma ML, Gupta M, Goebel A, marley K Percutaneous cervical cordotomy for cancer-related pain: prospective multimodal outcomes evaluation. BMJ Support Palliat Care 2020;bmjspcare-2019-002084.

Download references

Author information

Authors and Affiliations

  1. Main Regional Center of Pain Relief and Supportive/Palliative Care, La Maddalena Cancer Center, Via San Lorenzo 312, 90146, Palermo, Italy

    Sebastiano Mercadante

  2. Regional Home Care Program, SAMOT, Palermo, Italy

    Sebastiano Mercadante

Authors
  1. Sebastiano Mercadante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastiano Mercadante.

Ethics declarations

Conflict of interest

The author has not conflicts of interest to declare.

Funding

No funding was received for the preparation of this manuscript.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Data and code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mercadante, S. Cancer Pain Treatment Strategies in Patients with Cancer. Drugs 82, 1357–1366 (2022). https://doi.org/10.1007/s40265-022-01780-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-022-01780-6

Search

Navigation